GLP-1-based obesity drugs such as semaglutide and tirzepatide cause large reductions in body weight, and some of that weight is lean mass rather than fat. That finding has fueled concern that these medicines may cause dangerous muscle loss. The evidence is more nuanced: lean mass does decline during treatment, but fat mass falls more, and current studies do not show that every loss of lean tissue is equivalent to loss of functional skeletal muscle or clinical sarcopenia.
Semaglutide reduces lean mass, but it reduces fat mass more
The most cited semaglutide body-composition data come from an exploratory dual-energy X-ray absorptiometry, or DXA, substudy of STEP 1. The main STEP 1 trial randomized 1,961 adults with overweight or obesity without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, both with lifestyle intervention. The body-composition substudy included 140 participants, 95 assigned semaglutide and 45 placebo.
Among participants receiving semaglutide, body weight fell by 15.0% from baseline. Total fat mass fell by 19.3%, regional visceral fat mass by 27.4%, and total lean body mass by 9.7%. Because fat declined more than lean tissue, the proportion of body weight represented by lean mass actually increased by 3.0 percentage points.
Those numbers are often summarized as “muscle loss,” but DXA does not directly measure muscle fibers. Lean mass includes skeletal muscle, water, organs, connective tissue, and other non-fat components. A fall in DXA-measured lean mass therefore cannot be assumed to represent the same percentage loss of contractile muscle.
Tirzepatide shows a similar pattern in SURMOUNT-1
A body-composition substudy of SURMOUNT-1 provides a more recent comparison for tirzepatide. The substudy included 160 participants with baseline and week-72 DXA measurements, 124 receiving pooled tirzepatide doses and 36 receiving placebo.
With tirzepatide, body weight declined by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. The investigators calculated that approximately 75% of the weight lost was fat mass and 25% was lean mass. The placebo group showed a similar proportional split, even though the total amount of weight lost was much smaller.
That result matters because it argues against a simple interpretation that tirzepatide selectively strips muscle. Rather, the medication produces much greater total weight loss, and lean tissue is one component of that loss.
A 2026 meta-analysis found lean-mass loss is not unique to incretin drugs
A 2026 systematic review and meta-analysis compared body-composition changes with incretin therapies against intensive lifestyle interventions. Across 20 randomized controlled trials including 15,782 participants, lean mass accounted for 25% to 39% of total weight loss with incretin-based treatments.
For semaglutide, the pooled estimate was 35.2% of weight loss attributable to lean mass; for tirzepatide, 25.4%; and for liraglutide, 26.8%. Intensive lifestyle interventions without resistance training showed a similar proportion, 26.2%. The between-group comparison was not statistically significant.
The standout finding was that lifestyle programs including resistance training had the most favorable profile, with 17.5% of total weight loss attributable to lean mass. That supports a practical point: substantial weight loss itself carries some risk of lean-tissue loss, regardless of whether the weight is lost with medication or lifestyle intervention.
Lean mass loss is not the same as sarcopenia
Sarcopenia is a clinical syndrome involving loss of muscle quantity together with impaired strength or physical performance. A person can lose some lean mass while still improving function, relative strength, mobility, or metabolic health. Conversely, an older or frail person with limited muscle reserve may be more vulnerable to even a modest reduction in skeletal muscle.
This distinction is why body composition should be interpreted alongside muscle strength and physical performance, not as a single number. A September 2026 systematic review and meta-analysis found that GLP-1 receptor agonists were associated with reductions in lean body mass or fat-free mass, but the certainty of evidence was low and whether those changes translate into clinically meaningful impairment in muscle function or physical performance remains uncertain.
Older adults and people with low muscle reserve deserve more attention
The potential clinical concern is greatest in people who start treatment with less muscle reserve, including some older adults, people with frailty, and patients who are sedentary or already undernourished. Rapid weight loss combined with very low calorie or protein intake could amplify loss of muscle tissue.
Current large obesity trials were not designed primarily to diagnose sarcopenia, and many participants were middle-aged rather than very old or frail. That limits how confidently the trial averages can be applied to higher-risk populations.
Our semaglutide vs tirzepatide comparison explains how much total weight loss differs between the two drugs, while our GLP-1 side-effects guide covers the adverse effects more firmly established in randomized trials and prescribing information.
Resistance training is the clearest muscle-preservation strategy
Muscle is highly responsive to mechanical loading. Resistance exercise stimulates muscle protein synthesis and helps preserve strength during calorie restriction and weight loss. In the 2026 meta-analysis, programs that combined lifestyle intervention with resistance training showed less proportional lean-mass loss than lifestyle intervention alone.
Adequate dietary protein is also biologically important, but the optimal protein prescription specifically for people using semaglutide or tirzepatide has not been established in large randomized trials. Protein needs may also differ in chronic kidney disease, older age, and other medical conditions, so a single high-protein target should not be presented as universally appropriate.
The practical message is not that every person taking a GLP-1 drug needs a bodybuilding program. It is that weight-loss treatment should ideally preserve function as well as reduce fat mass, and some form of progressive resistance exercise is one of the better-supported ways to do that.
What the evidence cannot yet answer
The STEP 1 body-composition analysis was exploratory and involved only 140 of the 1,961 participants in the parent trial. The SURMOUNT-1 DXA substudy included only 160 of 2,539 participants. Both therefore represent selected subsets rather than the entire trial populations.
DXA also cannot separate all components of lean tissue or directly measure muscle quality. Trials have reported far less information about strength, gait speed, functional decline, and long-term sarcopenia than about total body weight. The clinical meaning of a given percentage reduction in lean mass may therefore differ substantially between a healthy 40-year-old and a frail 80-year-old.
The SURMOUNT-1 body-composition study included multiple Eli Lilly employees and shareholders among its authors, and the STEP program was sponsored by Novo Nordisk. Those industry relationships do not invalidate the randomized data, but they are relevant when interpreting exploratory and post hoc analyses.
The concern is real, but “GLP-1 drugs eat muscle” is too simplistic
Semaglutide and tirzepatide do reduce lean mass during major weight loss. They also reduce substantially more fat mass, including visceral fat, and the proportion of weight lost as lean tissue is broadly similar to what occurs during substantial lifestyle-driven weight loss. The unresolved question is not whether lean mass changes, but whether particular patients lose enough functional skeletal muscle to affect strength, mobility, or long-term health.
For now, the strongest evidence supports pairing obesity treatment with strategies that protect muscle, especially resistance exercise, and paying closer attention to older or frail patients rather than assuming all lean-mass loss is either harmless or catastrophic.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Suppl 1):A16-A17. DOI: 10.1210/jendso/bvab048.030.
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. DOI: 10.1111/dom.16275.
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026. DOI: 10.1111/dom.70666.
- Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs. 2026. DOI: 10.1007/s40265-026-02365-3.